A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Trial Profile

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Bb 2121 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man
  • Sponsors bluebird bio; Celgene Corporation
  • Most Recent Events

    • 21 Feb 2018 According to the bluebird bio media release, clinical data from this study will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in 2018
    • 21 Feb 2018 According to the bluebird bio media release, final patient to be enrolled in the study was dosed.
    • 21 Feb 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top